In a Class of its Own!

A clinical-stage biopharmaceutical company developing first-in-class venom-derived peptide therapies to transform patient outcomes.

Company

Our Pipeline Clinical Trials CB-24 Mode of Action Scientific Reviews The Team

Investors

Investor Relations Press Release Events

Contact

Get in Touch

Privacy Policy